[Treatment of plasmacytoma with hyperviscosity syndrome].
It is reported on the treatment of three patients with a hyperviscosity syndrome in IgG-plasmocytoma. Before every polychemotherapy cycle a plasma exchange was carried out, when the total protein in the serum and the immunoglobulins were essentially increased and clinical symptoms of the hyperviscosity syndrome were existing. The results and the possible effects on the efficacy of the therapy with cytostatic agents are discussed. In the light of our experiences we can recommend the membrane plasma filtration treatment as symptomatic therapeutic measure in the hyperviscosity syndrome.
Bosselmann
H P
HP
Nephrologischen Abteilung, Medizinischen Akademie Magdeburg.
Gaede
B
B
Franke
A
A
Lachhein
L
L
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001809:Blood Viscosity; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D010951:Plasma Exchange; D010954:Plasmacytoma / Q000097:blood / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D013577:Syndrome; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone
Die Behandlung des Plasmozytoms mit Hyperviskositätssyndrom.